EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography‐tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia

Martin H J Wiesen iD, Jannik Stemler iD, Cornelia Fietz iD, Carolin Joisten iD, Oliver A Cornely iD, Nick Verougstraete iD, Thomas Streichert iD, Carsten Müller iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Martin H J Wiesen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Drug Monitoring, Pharmacology at the Laboratory Diagnostics Centre, Faculty of Medicine and University Hospital Cologne, University of Co…. Hauptthemen laut MEDLINE: Staurosporine, Leukemia, Myeloid, Acute, Tandem Mass Spectrometry. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Midostaurin is an oral multitargeted tyrosine kinase inhibitor for the treatment of acute myeloid leukemia (AML). Therapeutic drug monitoring of midostaurin may support its safe use when suspecting toxicity or combined with strong CYP3A4 inhibitors.

Methods

A stable isotope dilution liquid chromatography–tandem mass spectrometry method was developed and validated for the determination and quantification of midostaurin in human plasma and serum. Midostaurin serum concentrations were analyzed in 12 patients with FMS‐like tyrosine kinase 3 (FLT3)‐mutated AML during induction chemotherapy with cytarabine, daunorubicin, and midostaurin. Posaconazole was used as prophylaxis of invasive fungal infections.

Results

Linear quantification of midostaurin was demonstrated across a concentration range of 0.01–8.00 mg/L. Inter‐ and intraday imprecisions of the proposed method were well within ±10%. Venous blood samples were taken in nine and three patients in the first and second cycle of induction chemotherapy. Median (range) midostaurin serum concentration was 7.9 mg/L (1.5–26.1 mg/L) as determined in 37 independent serum specimens.

Conclusion

In a real‐life cohort of AML patients, interindividual variability in midostaurin serum concentrations was high, highlighting issues concerning optimal drug dosing in AML patients. A personalized dosage approach may maximize the safety of midostaurin. Prospective studies and standardization of analytical methods to support such an approach are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StaurosporineLeukemia, Myeloid, AcuteTandem Mass SpectrometryHumansMaleFemaleMiddle AgedAgedChromatography, LiquidAdultDrug Monitoringfms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsReproducibility of ResultsCohort Studies

Stichwörter der Autor:innen

AMLCYP3A4LC–MS/MSmidostaurinposaconazoletherapeutic drug monitoring

Substanzen

midostaurinStaurosporinefms-Like Tyrosine Kinase 3Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Therapeutic Drug Monitoring, Pharmacology at the Laboratory Diagnostics Centre, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Clinical Chemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Univer…
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.

ORCID-Profile: Martin H J Wiesen, Jannik Stemler, Cornelia Fietz, Carolin Joisten, Oliver A Cornely, Nick Verougstraete, Thomas Streichert, Carsten Müller

Zitieren

APA

Wiesen, M. H. J., Stemler, J., Fietz, C., Joisten, C., Cornely, O. A., Verougstraete, N., Streichert, T., & Müller, C. (2024). Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography‐tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14178

Vancouver

Wiesen MHJ, Stemler J, Fietz C, Joisten C, Cornely OA, Verougstraete N, et al. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography‐tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia. European Journal of Haematology. 2024. doi:10.1111/ejh.14178

BibTeX
@article{Wiesen2024,
  author = {Wiesen, Martin H J and Stemler, Jannik and Fietz, Cornelia and Joisten, Carolin and Cornely, Oliver A and Verougstraete, Nick and Streichert, Thomas and Müller, Carsten},
  title = {Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography‐tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14178}
}
Kostenlos starten →